An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
American Thoracic Society |  |
| California TB Risk Assessments |  |
Confidential Morbidity Report – Tuberculosis
County of Orange, Health Care Agency, Public Health Services | |
Diagnosis of Tuberculosis in Adults and Children, 2017 Guidelines
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America | |
Diagnostic Standards and Classification of Tuberculosis in Adults and Children
American Thoracic Society | |
Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd Edition
Curry International Tuberculosis Center | |
Interferon Gamma Release Assays (IGRA's)
Centers for Disease Control & Prevention | |
Latent Tuberculosis Infection: A Guide for Primary Healthcare Providers
Centers for Disease Control & Prevention | |
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
Centers for Disease Control & Prevention | |
| Sample LTBI Treatment Record Book | |
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
Centers for Disease Control & Prevention, MMWR; vol. 49/No. RR-6 | |
| Three Months Once Weekly Isoniazid Plus Rifapentine (3HP) Trifold Pamphlet | |
Treatment of Tuberculosis
American Thoracic Society | |
Treatment of Drug-Susceptible Tuberculosis, 2016 Guidelines
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America | |
